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1. Introduction 
The gastrointestinal system consists of a hollow muscular tube starting from the oral cavity, 
where food enters the mouth, continuing through the pharynx, oesophagus, stomach and 
intestines to the rectum and anus, where faeces pass out. The primary purpose of the 
gastrointestinal system is to break down food into nutrients, which together with water can 
be absorbed to feed the body cells. In the case of gastrointestinal disease or disorders, these 
functions of the gastrointestinal tract are not achieved successfully, discussed in the 
subsequent sections of this chapter. The innermost layer of the gastrointestinal system is the 
mucosa, which is lined with specialised epithelial cells, supported by an underlying 
connective tissue layer called the lamina propria, where infiltrating leucocytes, in particular, 
myeloid linage leucocytes are often seen. 
2. The natural history of ulcerative colitis 
Ulcerative colitis (UC) is one of the two major phenotypes of the idiopathic inflammatory 
bowel diseases (IBD) of the intestine; the other major phenotype is Crohn’s disease (CD). UC 
and CD are both debilitating chronic disorders that afflict millions of individuals 
throughout the world with symptoms which impair function and quality of life. However, 
whereas UC is confined to the colon and the rectum, CD may affect any part of the gut from 
the mouth to the perianal (1,2). A multitude of clinical manifestations represent the 
expressions of IBD. These include diarrhoea, rectal bleeding, abdominal discomfort, fever, 
anaemia, and weight loss; both UC and CD tend to run a remitting-relapsing course affected 
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by diverse environmental factors (2). From here on, we shall focus only on UC. The severity 
of UC is often presented by clinical activity index (CAI). Another, but complementary 
parameter is endoscopic activity index, not used in this chapter. 
3. Colonoscope, the gastroenterologist’s eye and arms in modern times 
Colonoscopy is a revolutionary development in gastroenterology, now days like both arm 
and eyes for specialist gastroenterologists that can reach the inside of the large and distal 
segment of the small intestine. Introduced in the late 1960s (3), the term, colonoscopy refers 
to the endoscopic examination of the bowel with a charge-coupled device (CCD) camera or a 
fiber optic camera on a flexible tube passed through the rectal opening. As the name implies, 
colonoscopy allows a visual diagnosis of intestinal wall lesions like inflammation, 
ulceration, polyps and provides the opportunity for biopsy or removal of suspected 
cancerous lesions. Colonoscopy can remove polyps as small as one millimetre or less. Once 
polyps are removed, they can be studied with the aid of a microscope to determine if they 
are precancerous or not. Retrograde colonoscopy of the entire colon, and endoscopic 
excision of polyps from anywhere in the colon, began in 1969 (4). Momentous advances 
have occurred over the past two decades, and the two procedures are now widely accepted 
and practiced. Development and perfection of the methodology were, at first, fraught with 
many difficulties, both procedural and technical, which had to be overcome. Significant 
opposition was engendered in the early years by some who claimed that the methods were 
both unnecessary and unduly dangerous. Time has proven otherwise. Progress came about 
as the result of a steady stream of publications from a number of centres documenting the 
successful and safe application of the methodology.  
More advanced versions include virtual colonoscopy, which uses 2D and 3D imagery 
reconstructed from computed tomography (CT) scans or from nuclear magnetic resonance 
(MR) scans, is also possible, as a totally non-invasive medical test. However, unlike standard 
colonoscopy, virtual colonoscopy does not allow for therapeutic maneuvers such as 
polyp/tumour removal or biopsy nor visualization of lesions smaller than 5 millimeters. If a 
growth or polyp is detected by using CT colonography, a standard colonoscopy would still 
need to be performed. Further, colonoscopy is similar to, but not the same as, 
sigmoidoscopy, the difference being related to which parts of the colon each can examine. A 
colonoscopy allows an examination of the entire colon (measuring more than 1.5m in 
length). A sigmoidoscopy allows an examination of only the final 60cm of the colon. A 
sigmoidoscopy is often used as a screening procedure for a full colonoscopy to be followed 
in many instances in conjunction with a faecal occult blood test, which can detect the 
formation of cancerous cells throughout the colon. At other times, a sigmoidoscopy is 
preferred to a full colonoscopy in patients having an active flare of ulcerative colitis (UC) or 
Crohn's disease (CD) to avoid a perforation of the colon. Additionally, surgeons use the 
term pouchoscopy to refer to a colonoscopy of the ileo-anal pouch. Conditions that call for 
diagnostic colonoscopy include gastrointestinal haemorrhage, unexplained changes in 
bowel habit and suspicion of malignancy. Colonoscopies are often used to diagnose colon 
cancer, but are also frequently used to diagnose and assess inflammatory bowel disease 
(IBD). In older patients (sometimes even younger ones) an unexplained drop in haematocrit 
(one sign of anaemia) is an indication that calls for a colonoscopy, usually along with an 
oesophagogastroduodenoscopy, even if no obvious blood has been seen in the stool (faeces). 
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Due to the high mortality associated with colon cancer and the high effectiveness and low 
risks associated with colonoscopy, it is now becoming a routine screening test for people 50 
years of age or older. Subsequent re-screenings are then scheduled based on the initial 
results found, with a five or ten-year recall being common for colonoscopies that produce 
normal results (5). Patients with a family history of colon cancer are often first screened 
during their teenage years. A recent study found that among people who have had an initial 
colonoscopy that found no polyps, the risk of developing colorectal cancer within five years 
is extremely low. Therefore, there is no need for those people to have another colonoscopy 
sooner than five years after the first screening (6). In this chapter, the authors endeavour to 
describe the potential diagnostic power of colonoscopy potentially to identify patients with 
an active flare of UC who are most likely to respond to selective, but therapeutic removal of 
circulating myeloid linage leucocytes (granulocytes and monocytes/macrophages) by 
extracorporeal adsorption, as a new and non-pharmacologic treatment intervention for 
patients with IBD, better known as GMA, which stands for granulocyte and monocyte 
adsorption (7). 
4. Colonoscopy in inflammatory bowel diseases 
Figure 1 shows colonoscopy photographs from the surface of the colonic mucosa of healthy 
human subjects or patients with UC following full remission in association with GMA 
therapy. The mucosa is the surface through, which nutrients and water from the food in the 
intestine are absorbed into the blood stream. Accordingly, healthy mucosa is typically well 
vascularised for adequate absorption. Colonoscopy has a unique position in viewing and 




Most symptoms of UC are due to the ulceration and the loss of the mucosal layer covering 
the inner wall of the large intestine (colon and the rectum). As the mucosal layer is involved 
in the absorption of nutrients and water from the gut, during severely active UC, absorption 
of nutrients and water is seriously impaired. In Figure 2, typical colonoscopy photographs 
from the surface of the colon or the rectum of patients with severe and fulminant UC are 
seen. There is extensive and deep ulcers together with near total loss of the mucosal tissue. 
This condition is debilitating, the patients may suffer from weight loss, and impaired quality 
of life. For example unabsorbed food and water will pass as watery diarrhoea, or bloody 
diarrhoea due to bleeding. Such patients are not likely to respond to any drug based 
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medication or even to therapeutic depletion of myeloid leucocytes by GMA, they have 
fulminant (disease persists in the presence of optimal medication) UC and often must opt 
for surgery known as colectomy. Needless to say that only an initial diagnostic colonoscopy 
can identify such patients as non-responders to drug based interventions so that the patient 
can opt for colectomy at an early stage. This should significantly shorten morbidity time and 
save medical cost.  
 
 
Fig. 2.    
5. Therapeutic options for patients with ulcerative colitis 
Despite the recognition of a genetic background together with environmental factors, which 
at present are thought to translate into an inappropriate inflammatory response in patients 
with UC (2, 8-10), currently our understanding on the immunopathogenesis of UC is 
inadequate. Hence, up to now drug therapy of UC has been empirical rather than based on 
sound understanding of disease aetiology. Accordingly, while drug therapy initially 
appears successful in the majority of patients, it comes at the cost of significant side effects 
(11,12). Further, up to now, first line medications for exacerbation of UC include 5-
aminosalicylic acid (5-ASA) or sulphasalazine in combination with a corticosteroid with 
consideration of azathioprine (or 6-mercaptopurine) and nutritional support for some 
patients (2,14-18). Treatment failure in patients with severe disease has often been an 
indication for colectomy in up to 40% of steroid refractory patients (2,19, 20) although in 
recent years, cyclosporin A (CsA) has been introduced for corticosteroid refractory UC 
(18,21). Despite being moderately effective in this clinical setting in reducing colectomy 
rates, there remain serious concerns over long-term efficacy and toxicity of CsA (22). 
However, this is not to say that drug has no place in the treatment of UC. In fact, no one can 
deny the role of medicines in the elimination of most disease that our ancestors were left 
defenseless against. However, even in today’s era of modern medicine, it is essential to bear 
in mind that drug therapy by its very nature, involves adding a foreign substance to the 
body system and although initially effective, may lead to the disease becoming drug 
dependent or refractory. Additionally, many drugs are associated with toxic side effects 
which can add to the disease complexity. Hence, a therapeutic strategy based on a non-drug 
intervention, a correction or support of body’s natural processes like GMA (which takes 
away from the body instead of adding to it), if effective, should have advantages over drugs, 
long term adverse side effects and refractoriness are unlikely (23, 24). 
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6. Myeloid leucocytes, cytokines and ulcerative colitis 
It is now known that UC is exacerbated by inflammatory cytokines like tumour necrosis 
factor (TNF)-ǂ, interleukin (IL)-1ǃ, IL-6, IL-8 and others (25). Accordingly, anti-cytokine 
antibodies, notably anti-TNF antibodies like infliximab (IFX) are being used and new 
antibodies are being developed for the treatment of IBD (26). Indeed, the efficacy of anti-
TNF, notably IFX, in patients with CD (27) as well as in UC (26) has validated the role of this 
cytokine in the immunopathogenesis of IBD. However, the enthusiasm towards biologicals 
is increasingly being dampened by concerns about their long-term efficacy and in particular, 
the safety profiles (28,29). However, patients with active IBD harbour elevated and activated 
myeloid linage leucocytes (granulocytes and monocytes) in the presence of compromised 
lymphocytes (1,30-33). Further, histologic examinations of mucosal biopsies from patients 
with active IBD reveals a spectrum of pathologic manifestations among which an abundance 
of neutrophils accounts not only for the morphologic lesions in IBD, but also for the 
prevailing patterns of mucosal inflammation (2,34,35). When activated, myeloid leucocytes 
produce an array of pleiotropic cytokines like TNF-ǂ, IL-1ǃ, IL-6, IL-12, IL-23, which are 
strongly pro-inflammatory (25,36). Therefore, targeting leucocytes as key players in the 
exacerbation of IBD is what lies behind extracorporeal granulocyte monocyte/macrophage 
adsorption (GMA) with the Adacolumn (7). Likewise, neutrophils in patients with IBD show 
activation behaviour (30) and prolonged survival time (37). Factors that are known to 
promote neutrophil survival in IBD include inflammatory cytokines (38) and paradoxically 
corticosteroids (39), which are commonly used to treat IBD patients. Myeloid leucocytes, like 
the CD14(+)CD16(+) monocytes are major sources of TNF-ǂ (40,41), and it could be valid to 
say that selective depletion of myeloid leucocytes by GMA should alleviate inflammation 
and promote remission or at least enhance the efficacy of pharmacologics. However, clinical 
studies in patients with UC have reported unmatched efficacy outcomes, ranging from an 
85% (42) to a statistically insignificant level (43), indicating that certain subpopulations of 
patients benefit from GMA while others not so, suggesting that patients’ baseline 
demographic variables determine clinical response to this non-pharmacologic mode of 
therapy (23,24). 
7. Therapeutic leucocytapheresis in ulcerative colitis – logics and 
mechanisms 
For an extracorporeal intervention to be a novel non-drug therapeutic option, it should be 
able to selectively deplete leucocytes, which in patients with UC are thought to contribute 
to the disease pathogenesis. For example, we have already said that patients with active 
IBD are found to have compromised lymphocytes (31-33). With this in mind, certain sub-
populations of lymphocytes like the CD4(+)CD25(+) phenotype, known as the regulatory 
T cells (Treg) have essential immunoregulatory roles and therefore, are indispensable to 
the host (44-49). Based on these understandings, the Adacolumn leucocytapheresis system 
is designed to spare lymphocytes. It is filled with specially designed cellulose acetate 
beads of 2mm in diameter as the column leucocytapheresis carriers that are bathed in 
physiologic saline (50). The carriers remove from blood in the column most of the 
granulocytes, monocytes/macrophages together with some platelets (7,51). Surprisingly, 
the procedure has been associated with a sustained increase in absolute lymphocyte 
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counts in the post treatment phase (32,33,50) including the regulatory phenotype, 
CD4(+)CD25(+) Treg (7,49,50). The Adacolumn is an adsorptive type and 
leucocytapheresis with this column is often abbreviated as GMA. The mechanisms for 
sparing lymphocytes are briefly described here. Patients with immune dysfunction may 
have immune complexes (IC) in their plasma (7,51,52). Cellulose acetate adsorbs 
immunoglobulin G (IgG) and IC from the plasma (52,53). Upon adsorption, the binding 
sites on IgG and IC become available for the FcǄ receptors (FcǄRs) on myelocytes (7,51-
53). Further, cellulose acetate with adsorbed IgG and IC generates complement activation 
fragments including C3a and C5a (7,52,53). The opsonins C3b/C3bi and others derived 
from the activation fragments also adsorb onto the carriers and serve as binding sites for 
the leucocyte complement receptors, CR1, CR2, CR3 (Mac-1, CD11b/CD18). Hence, 
leucocyte adsorption to the GMA carriers in the Adacolumn is governed by the opsonins, 
FcǄRs and the leucocytes complement receptors (7,53). The expressions of these sets of 
receptors are common features of myeloid linage leucocytes. Lymphocytes are not known 
to express complement receptors except on small subsets of B, T and natural killer (NK) 
cells. Similarly, FcǄRs are not widely expressed on lymphocytes except on small 
populations of CD19+B cells and CD56+NK cells (7,51). These basic phenomena proceed 
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8. Colonoscopic features of typical responders to GMA 
Clinical experience has shown that GMA in patients with steroid dependent or steroid 
refractory UC was associated with significant efficacy as assessed by measuring the fall in 
UC clinical activity index (CAI) and tapering or discontinuation of steroids, while in steroid 
naïve patients, GMA spared patients from exposure to steroids (23,24). Therefore, published 
data (23,24,32,34,55) suggest that steroid naive patients respond particularly well. 
Characteristically they respond faster with fewer GMA sessions and have a high cumulative 
rate of remission. Thus, the remission rate in steroid naïve patients reported by Suzuki et al. 
(32) was an 85%. Similarly, Tanaka et al. (34) treated a cohort of 45 patients, 26 steroid naive 
and 19 steroid dependent. Each patient could receive up to a maximum of 11 GMA sessions 
(or until CAI decreased to 4 or less). At week 12, the response rate (CAI ≤4) in steroid naïve 
subgroup was 22 of 26 patients (84.6%) and in steroid dependent sub-group was 11 of 19 
(57.9%). Colonoscopy revealed that most non-responders in both groups had deep colonic 
ulcers and extensive loss of the mucosal tissue. Further, this is the only study that looked at 
the impact of GMA on leucocyte level in the colonic mucosa. Biopsies taken during 
colonoscopy revealed massive infiltration of the colonic mucosa by neutrophils and GMA 
was associated with a striking reduction of neutrophils in the mucosa (Figure 5). Tanaka’s 
colonoscopic observations (23,34) echo those of Suzuki et al. a few years earlier (32), who 
also reported that the only 3 non-responders in their cohort of 20 steroid naïve patients had 
deep colonic ulcers. In a very thorough study by Suzuki et al. (56), the authors aimed at 
determining the responders to GMA. Their major findings are as follows. Seven days after 
the last GMA session, 20 of 28 patients (71.4%) achieved clinical remission including all 8 
patients who had their first UC episode. The mean duration of UC in the 8 first episode 
 
 
Fig. 4.    
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cases was just 3.4 months compared with 40.2 months for all 28 patients and 65.4 months for 
the 8 patients who did not respond at al. The response to GMA seemed to be independent of 
baseline CAI. The authors concluded that first UC episode and short disease duration might 
be good predictors of response to GMA in that clinical setting. Further, they stated that 
GMA could be an effective first line medication for steroid naïve patients (23,32,56).  
9. The impact of GMA on mucosal leucocytes 
It is of particular interest to see if GMA, in fact does impact the mucosal level of infiltrating 
myeloid leucocytes. As stated above, colonic biopsies were taken from active disease sites 
before and after GMA induced remission in patients with active UC. Figure 5 shows 
representative histology photographs from a GMA responder patient. The specimen taken 
at baseline shows the colonic mucosa is infiltrated by a vast number of inflammatory 
leucocytes, primarily granulocytes and monocytes/macrophages; the density of the 
infiltrating cells was strongest in or around the glandular lumen (crypt abscesses). The 
specimen taken when the patient had achieved remission shows very striking reduction in 
inflammatory cell infiltrate. Surprisingly, the density of leucocytes was reported to be 
stronger in steroid naïve patients vs patients on steroids, suggesting that corticosteroids 
have inhibitory effects on neutrophils (23). 
 
 
Fig. 5.    
10. Colonoscopic features of non-responders to GMA 
As reviewed above, several studies have reported that any patient with a fair level of colonic 
mucosa is a potential responder to GMA. In contrast, Figure 2 (above) shows deep and 
extensive colonic lesions with virtually no mucosal tissue left at the lesion sites in two 
typical GMA non-responder patients. Such patients are unlikely to respond to any 
medication except colectomy. Even patients with a near equal CAI score had very different 
mucosal damage status, indicating that CAI per se does not reflect the full extent of mucosal 
damage in patients with UC. Figure 6 shows colonoscopy photographs from the colonic 
mucosa of a 60-year-old steroid dependent patient who showed partial response to GMA. 
At baseline, the major colonoscopic findings seen are strong inflammation with multiple 
polyp-like protrusions in the mucosa. Following a course of GMA therapy, inflammation 
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has alleviated, but multiple polyps are exposed and apparently seem not to be affected by 
GMA, but the mucosa appears to be regenerating once again, suggesting a fair level of 
mucosal tissue was left prior to the initiation of GMA therapy. Based on CAI, this patient 
might be in clinical remission, but has not achieved endoscopic (colonoscopic) remission, 
which could require a long observation time.  
A small minority of patients without deep colonic lesions or extensive loss of the mucosal 
tissue do not respond to GMA as well. Colonoscopy photographs from such patients are 
presented in Figure 7, showing inflammation, but without extensive ulcers (entry CAI, 15). 
These cases are likely to have a long history of multiple drug therapy. However, no patient 
with the entry colonoscopy features seen in Figure 2 did show any significant fall in CAI score. 
 
 
Fig. 6.    
 
 
Fig. 7.    
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11. Colonoscopic features of patients who are most likely to respond to GMA 
From the plethora of published clinical observations, it appears that drug naïve patients 
with superficial lesions, usually first episode cases are the best responders to GMA, respond 
soon after a few GMA sessions and can be spared from multiple drug therapy. Typical 
colonoscopic features in these patients are seen in Figure 8. Accordingly, GMA should have 




Fig. 8.    
12. Concluding remarks 
The gastrointestinal system is often affected by diseases which can impair its function and 
the individual’s well being. The colonoscope may be regarded as the gastroenterologist’s 
eyes and arms. Within limits, surgery can be achieved by the application of colonoscope like 
removing suspected cancerous lesions and excision of polyps which grow inside the large 
intestine in many individuals and can cause morbidity. Further, the large intestine is the 
main organ where IBD, in particular UC develops as a very debilitating health disorder. UC 
patients present with diverse clinical and endoscopic disease severity levels, and therefore, 
their clinical response to medical interventions can be complete remission, partial response 
or no response at all. Therefore, without colonoscopic evaluations of patients’ relevant 
demographic variables, medical resources will be wasted together with prolonged 
morbidity time for many patients. Further, patients with UC have activated myeloid 
leucocytes, which infiltrate the colonic mucosa in vast numbers and potentially can 
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exacerbate the inflammation and perpetuate the disease. Accordingly, efficient depletion of 
myeloid leucocytes by GMA, which reduces the mucosal concentrations of myeloid 
leucocytes, should benefit patients with UC. In spite of this view, clinical efficacy outcomes 
are both encouraging as well as disappointing; the answer might lie in the patients’ disease 
status at entry. By the power of colonoscopy over a decade in patients with UC we have 
learnt that all patients with the first UC episode and short duration of disease readily 
respond to GMA and can be spared from multiple drug therapy. Similarly, most steroid 
naïve or dependent patients who have a fair level of intact mucosal tissue are potential 
responders to GMA. Patients with extensive loss of the mucosal tissue and those with a long 
history of exposure to multiple drugs like corticosteroids are unlikely to respond to GMA. 
Further, one of the most favoured features of Adacolumn GMA is its safety profile. Serious 
side effects are very rare. This is in sharp contrast to multiple severe side effects associated 
with most conventional pharmacologicals and new biologics. Our view is that in patients 
with UC, there is an evolving scope for therapeutic opportunity based on taking away the 
sources of inflammatory cytokines.  
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